此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression

2015年3月24日 更新者:Hoffmann-La Roche

A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy

This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based chemotherapy without progression. Patients will receive Tarceva at a dose of 150 mg orally daily until disease progression or unacceptable toxicity occurs.

研究概览

地位

完全的

干预/治疗

研究类型

介入性

注册 (实际的)

51

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bangalore、印度、560027
      • Chennai、印度、600035
      • Delhi、印度、110085
      • Hyderabad、印度、500 034
      • Jaipur、印度、302 017
      • Kolkata、印度、700026
      • Nasik、印度、422005

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult patients ≥ 18 years of age.
  • Histologically documented non-small cell lung cancer (NSCLC).
  • Locally advanced or recurrent (Stage IIIB) or metastatic (Stage IV) disease.
  • Completion of 4 cycles of an acceptable, standard, platinum-based chemotherapy doublet without progression.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Patients of reproductive potential must agree to use effective contraception.

Exclusion Criteria:

  • Prior exposure to agents directed at the human epidermal growth factor receptor (HER) axis (eg, gefitinib, cetuximab, trastuzumab).
  • Prior treatment with any monoclonal antibody therapy.
  • Any other malignancies within the previous 5 years, except for adequately treated carcinoma in situ of the cervix or squamous cell skin cancer.
  • Clinically significant cardiovascular, hepatic, renal, or metabolic disease or active infection
  • Pre-existing interstitial lung disease.
  • Human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
  • Pregnant or lactating women.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Erlotinib
Participants received erlotinib 150 mg orally once a day for 48 weeks.
Erlotinib was supplied as tablets.
其他名称:
  • 特罗凯

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants With Progression-free Survival at Week 52
大体时间:From the date of enrolment in the study until the date of disease progression or death from any cause (up to 2 years, 6 months).
A participant had progression-free survival if they did not have disease progression and were alive. Tumor assessments were done by magnetic resonance imaging according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-target lesions. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter.
From the date of enrolment in the study until the date of disease progression or death from any cause (up to 2 years, 6 months).

次要结果测量

结果测量
措施说明
大体时间
Progression-free Survival (PFS)
大体时间:From the date of enrolment until the end of the study (up to 2 years, 6 months).
PFS was defined as the time from the date of enrolment to the date of disease progression (PD) or death, whichever occurred first. Tumor assessments were done by magnetic resonance imaging according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions (TL), taking as reference the smallest sum longest diameter recorded since treatment started or the unequivocal progression of existing non-TLs. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all involved organs, should be identified as TLs at Baseline. TLs should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all TLs will be calculated and reported as the Baseline sum longest diameter.
From the date of enrolment until the end of the study (up to 2 years, 6 months).
Overall Survival
大体时间:From the date of enrolment until the end of the study (up to 2 years, 6 months).
Overall survival was defined as the time from the date of enrolment to the date of death from any cause.
From the date of enrolment until the end of the study (up to 2 years, 6 months).
Percentage of Participants With a Complete Response (CR) or a Partial Response (PR)
大体时间:From the date of enrolment until the end of the study (up to 2 years, 6 months).
A CR was defined as the disappearance of all target lesions. A PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the Baseline sum longest diameter. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all involved organs, should be identified as target lesions at Baseline. All other lesions (or sites of disease) should be identified as non-target lesions. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the Baseline sum longest diameter. Tumor assessments were done by magnetic resonance imaging according to RECIST v1.1.
From the date of enrolment until the end of the study (up to 2 years, 6 months).
Percentage of Participants With Disease Control
大体时间:From the date of enrolment until the end of the study (up to 2 years, 6 months).
A participant with disease control was defined as a participant with either a complete response (CR), a partial response (PR), or stable disease (SD), as determined using RECIST v1.1. A CR was defined as the disappearance of all target lesions (TL). A PR was defined as at least a 30% decrease in the sum of the longest diameter of TLs taking as reference the Baseline sum longest diameter (SLD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the unequivocal progression of existing non-TLs. A SLD for all TLs will be calculated and reported as the Baseline SLD. Tumor assessments were done by magnetic resonance imaging according to RECIST v1.1.
From the date of enrolment until the end of the study (up to 2 years, 6 months).

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年3月1日

初级完成 (实际的)

2013年9月1日

研究完成 (实际的)

2013年9月1日

研究注册日期

首次提交

2010年10月28日

首先提交符合 QC 标准的

2010年10月28日

首次发布 (估计)

2010年10月29日

研究记录更新

最后更新发布 (估计)

2015年3月30日

上次提交的符合 QC 标准的更新

2015年3月24日

最后验证

2015年3月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅